You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
A New Class of Broad-Spectrum Antibacterial Agents to Treat Multi-Drug Resistant Pathogens
SBC: Curza Inc Topic: NIAIDProject Summary Cūrza is developing the CZ-02 platform of broad-spectrum antibiotics as a new class focusing on multidrug- resistant (MDR) Gram-negative pathogens that will also be efficacious against Gram-positive bacteria. CZ-02 antibacterials bind to a unique site on the bacterial ribosome that is not targeted by antibiotics available clinically which is expected to limit cross-resistance to o ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Automated Seizure Detection for Home Seizure Monitoring with Epilog Sensors
SBC: EPITEL, INC. Topic: 105ABSTRACT Aura is a digital health platform that uses Epilog™, a miniature, wireless, wearable EEG sensor worn on the scalp below hairline that can record clinical and subclinical seizures. After an initial diagnosis of epilepsy, an epileptologist will use known information about patients’ seizures to guide the best scalp location to place the Epilog EEG sensor (A). EEG data is continuously tra ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of a Diagnostic Test for Eosinophilic Chronic Rhinosinusitis
SBC: GLYCOMIRA, LLC Topic: NIAIDPROJECT SUMMARYThe goal of this proposal is to optimize and clinically validate a new diagnostic test for eosinophilic chronic rhinosinusitis (eCRS) at the point-of-care, improving the efficiency, value, and accessibility of personalized medicine. eCRS affects up to 5 million Americans and is characterized by varying degrees of sinonasal and peripheral eosinophilia, linked to treatment responsiven ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Commercial translation of high-density carbon fiber electrode arrays for multi-modal analysis of neural microcircuits
SBC: BLACKROCK MICROSYSTEMS, INC Topic: 106ABSTRACT The ability to measure and manipulate local brain circuit activity in living, behaving animals is essential to understanding the complexities of brain function and dysfunction. A novel, penetrating high-density carbon fiber electrode array composed of flexible, ultrathin conductive carbon microfibers was recently developed under the BRAIN Initiative to study neural microcircuit dynamics. ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
3D Printed Silicon Nitride Porous PEEK Composite Spinal Cages for Anti-Infection
SBC: SINTX TECHNOLOGIES, INC. Topic: NIAMSPROJECT SUMMARYSpinal fusion is the standard treatment for persistent neck and back pain, but the hardware used to stabilize the fusion can harbor or even promote bacteria that lead to persistent, difficult-to-treat infections that are costly and damaging to patient health. Among the available materials for spinal fusion, polyether-ether-ketone (PEEK) cages stand out due to their strength, biocomp ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
CUSTOMIZABLE TRAINING SOFTWARE FOR PROFESSIONAL ALZHEIMER DIRECT CARE PROVIDERS
SBC: Proactive Memory Services Topic: RCUSTOMIZABLE TRAINING SOFTWARE FOR PROFESSIONAL ALZHEIMER DIRECT CARE PROVIDERSProject Summary/Abstract - ProActive Memory Services, Inc. New strategies are urgently needed to improve Alzheimer’s disease and related dementias (AD/RD) training for 4.6 million professional direct care providers that assist 8.3 million older adults in the US. Assisted living facilities (ALF) and personal care agenc ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
REMI Platform for Remote EEG Monitoring
SBC: EPITEL, INC. Topic: NINDSABSTRACT REMI Platform for Remote EEG Monitoring The REMI EEG screening platform. The REMI app running on a medical tablet guides staff through the placement of four Epilog sensors. Epilog transmits EEG through Bluetooth to the app which then relays the data to a cloud server running Persyst EEG reviewing software. An epileptologist logs on to Persyst Mobile to remotely review Epilog EEG in real t ...
SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
Dual-Tracer PET Tumor Imaging
SBC: MULTIFUNCTIONAL IMAGING, LLC Topic: 102AbstractPositron emission tomography (PET, including PET/CT and PET/MRI) with 18F-fluorodeoxyglucose (FDG) plays a key role in diagnosing and staging a wide variety of malignant tumors, assessing tumor grade, and evaluating response to therapy. The advent of other recently-approved tracers, particularly those with theranostic partners, is opening a new era of imaging where the uptake of PET tracer ...
SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
Topical Eyedrops Increasing Lysyl Oxidase Activity to Control Myopia
SBC: Iveena Delivery Systems, Inc. Topic: NEIProject Summary Pediatric myopia, also known as nearsightedness, is an eye condition in which one is unable to bring distant objects into proper focus. It is the leading cause of vision impairment in the world. The estimated economic impact of uncorrected refractive error is estimated to be a loss of $202 billion of global gross domestic product. The prevalence of myopia and high myopia are increa ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
A Potent D-peptide Inhibitor of TNFα for Treatment of Rheumatoid Arthritis
SBC: D BioTherapeutics, LLC Topic: NIAMSRheumatoid arthritis (RA) is a chronic, debilitating inflammatory disease with high medical and societal costs afflicting more than 1.6 million Americans. Blockade of TNFα-driven inflammation with approved anti-TNFα biologics (such as Humira®, Remicade®, Simponi®, and Enbrel®) is an effective treatment for many patients suffering from RA. However, due at least in part to the immunogenicity o ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health